Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 30, 2009

Link Technologies Licenses University of Manchester’s Platform to Reduce Background Fluorescent Signal

  • Link Technologies licensed The University of Manchester Intellectual Property’s (UMIP) exciplex technology. Under the terms of the license, Link will manufacture and sell exciplex-based diagnostic reagents worldwide.

    Exciplex technology offers ultra-biospecificity and increases detection sensitivity over conventional systems due to negligible background signal, according to UMIP. Researchers from the university developed new exciplex diagnostic probes based on labeling oligonucleotides with exciplex partners that form excited-state complexes in close spatial proximity. Application of these modified oligonucleotides in diagnostic systems has been shown to discriminate DNA mutations at the level of PCR products and plasmid DNA, UMIP scientists claim.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »